CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company today announced the launch of the Company’s eight presentations of heparin sodium ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Heparin Sodium Injection (5,000 USP units per mL) in the company’s Simplist™ ready ...
- Nine Heparin Vials to be Differentiated with PreventIV Measures(TM) Packaging and Labeling Features - Download image SCHAUMBURG, Ill., July 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a ...
Tarrytown, NY - Early phase III results from the PROTECT trial looking at an oral heparin formulation for the prevention of deep vein thrombosis (DVT) in total hip replacement surgery patients show ...
Patients hospitalized with fractures typically receive an injectable blood thinner, low-molecular-weight heparin, to prevent life-threatening blood clots. A new clinical trial, however, found that ...
THE chief obstacles to the wide-scale use of heparin in the treatment of venous thromboembolic disease, are two: the expense of the available commercial heparin preparations and the transiency of ...
Government regulators told doctors Monday to switch from using a blood thinner made by Baxter International, following hundreds of reports of allergic reactions. The Food and Drug Administration said ...
The oral anticoagulant drug apixaban may offer a safer, more effective alternative to standard home heparin injections for patients taking extended prophylaxis (EP) to prevent blood-clot-related ...
BOSTON (MarketWatch) -- Baxter International late Friday issued an "urgent" recall of batches of its blood-thinner heparin due to reports they have caused severe allergic reactions in some recipients.
Patients who have surgery to repair bone fractures typically receive a type of injectable blood thinner, low-molecular-weight heparin, to prevent life-threatening blood clots, but a new clinical trial ...
Patients hospitalized with fractures typically receive an injectable blood thinner, low-molecular-weight heparin, to prevent life-threatening blood clots. A new clinical trial, however, found that ...